4.8 Article

Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 122, Issue 12, Pages 4424-4438

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI64537

Keywords

-

Funding

  1. NIH [R01HL-093242, P20 RR018758, NS36251, DK45735, P01HL085607, R01 HL085789, R01 HL109420]
  2. Oklahoma Center for Advanced Science and Technology (OCAST)
  3. American Heart Association [0835544N]
  4. Associazione Italiana per la Ricerca sul Cancro (AIRC)
  5. Association for International Cancer Research - UK (AICR-UK)
  6. Telethon
  7. CARIPLO
  8. Interlink
  9. COFIN/PRIN

Ask authors/readers for more resources

Epsins are a family of ubiquitin-binding, endocytic clathrin adaptors. Mice lacking both epsins 1 and 2 (Epn1/2) die at embryonic day 10 and exhibit an abnormal vascular phenotype. To examine the angiogenic role of endothelial epsins, we generated mice with constitutive or inducible deletion of Epn1/2 in vascular endothelium. These mice exhibited no abnormal phenotypes under normal conditions, suggesting that lack of endothelial epsins 1 and 2 did not affect normal blood vessels. In tumors, however, loss of epsins 1 and 2 resulted in disorganized vasculature, significantly increased vascular permeability, and markedly retarded tumor growth. Mechanistically, we show that VEGF promoted binding of epsin to ubiquitinated VEGFR2. Loss of epsins 1 and 2 specifically impaired endocytosis and degradation of VEGFR2, which resulted in excessive VEGF signaling that compromised tumor vascular function by exacerbating nonproductive leaky angiogenesis. This suggests that tumor vasculature requires a balance in VEGF signaling to provide sufficient productive angiogenesis for tumor development and that endothelial epsins 1 and 2 negatively regulate the output of VEGF signaling. Promotion of excessive VEGF signaling within tumors via a block of epsin 1 and 2 function may represent a strategy to prevent normal angiogenesis in cancer patients who are resistant to anti-VEGF therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available